Ibutilide Fumarate Acute Cardioconversion And Atrial Flutter Antiarrhythmic Agent
Contact Person : Jimmy Tian
Phone Number : 86-18602905046
WhatsApp : +8618602905046
Minimum Order Quantity : | 30,000 ampoules | Price : | to be negotiated |
---|---|---|---|
Packaging Details : | 50 ampoules/box, 30 Boxes/carton | Delivery Time : | 30 days |
Payment Terms : | T/T, L/C | Supply Ability : | 50,000,000 ampoules/ month |
Place of Origin: | China | Brand Name: | LIBANG |
---|---|---|---|
Certification: | Chinese GMP |
Detail Information |
|||
Function: | Local Anesthetic | Strength: | 5ml:500mg |
---|---|---|---|
Pack: | 50amps /box | Storage: | At 20 - 25oC |
Batch Quantity: | 30,000 Capsules | Shelf-life: | 24 Months |
High Light: | Cas 137 58 6 Lidocaine Hydrochloride Injection,Lidocaine Injection 5ml : 50mg,Cas 137 58 6 Local Anesthetic Injection |
Product Description
LIDOCAINE HYDROCHLORID INJECTION 5mL:50mg
Lidocaine Hydrochloride Injection is a sterile, nonpyrogenic solution of an antiarrhythmic agent administered intravenously by either direct injection or continuous infusion. Lidocaine Hydrochloride is chemically designated 2-(Diethylamino)-2’,6’-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula:
CLINICAL PHARMACOLOGY
Mechanism of Action: Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Pharmacokinetics: Lidocaine is rapidly metabolized by the liver and less than 10% of a dose is excreted unchanged in the urine. Oxidative N-dealkylation, a major pathway of metabolism, results in the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological /toxicological activities of these metabolites are similar to but less potent than lidocaine. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline. The elimination half-life of lidocaine is approximately 90–120 minutes in most patients. This may be prolonged in patients with hepatic impairment (average 343 minutes) or congestive heart failure (average 136 minutes). Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine HCl required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0μg free base per mL. In the rhesus monkey arterial blood levels of 18–21 µg/mL have been shown to be threshold for convulsive activity.
INDICATIONS AND USAGE
Lidocaine hydrochloride injection administered intravenously or intramuscularly, is specifically indicated in the acute management of ventricular arrhythmias such as those occurring in relation to acute myocardial infarction, or during cardiac manipulation, such as cardiac surgery.
Enter Your Message